Why they built it
23andMe's founders wanted to make genetic information a direct-to-consumer product while assembling a large consented dataset for research, with drug discovery part of the ambition from early on. The product combined a mailed saliva kit and laboratory analysis with online ancestry, trait, carrier-status and health-risk reports sold via its website and Amazon, including as gifts, with optional relative matching. Each buyer got personal results while those who separately consented contributed genetic and survey information to a larger cohort described in court as approximately 13 million customers with more than 80% research participation.
How it ended
The company did not shut the consumer service as a failure; after entering bankruptcy on March 23, 2025, its consumer genetics and research businesses were purchased by TTAM Research Institute on July 14 and continue under the nonprofit now known as 23andMe Research Institute, while the debtor became the separate Chrome Holding Co. The operating company ran out of financial room because a large cohort did not produce enough near-term revenue to fund its combined consumer, research, therapeutics and care scope, with fiscal-year revenue falling to about US$220 million from US$299 million and an adjusted EBITDA loss of US$176 million reported in May 2024. The US$302.5 million received at closing was an asset-transaction price, not an equity valuation or payout to former shareholders.
What went wrong
Most important first.
- 1
Scope outran near-term revenue Capital
The May 2024 results reported about US$220 million in revenue down from US$299 million with a US$176 million adjusted EBITDA loss and US$216 million of cash, supporting a financing mismatch where the cohort did not fund the chosen scope.
- 2
Kit, telehealth and partnership revenue declined Monetization
The company attributed the decrease to lower kit volumes and telehealth orders plus the end of GSK's exclusive discovery term, which ended in July 2023 before a nonexclusive license with a US$20 million data-access fee, with membership growth only partly offsetting declines.
- 3
Health claims required regulatory clearance Regulation
The FDA required the company to stop marketing health-related tests in the US in 2013 pending review, then in 2017 authorized genetic health-risk tests for ten conditions while stressing that genetic risk does not determine disease.
- 4
Breach made security a product and deal problem Technology
Attackers in the 2023 breach reused credentials stolen elsewhere while 23andMe lacked appropriate authentication, download protections and threat detection, leading to a £2.31 million UK fine involving 155,592 UK residents.
- 5
Governance fractured during retrenchment Team
Independent directors resigned in September 2024 citing differences over strategy, concentrated founder voting power and the absence of an actionable take-private proposal, followed by a November 2024 cut of roughly 40% of staff and a stop to therapeutics development.
What could be different today
- Controlled-access research sale is demonstrated: Discover23 launched in January 2025 with Lifebit's controlled environment for authorized collaborators to analyze summarized findings, and a Mirador collaboration sold targeted aggregated data, showing research access without funding own drug programs.
- Withdrawal tooling already exists to beat: OpenSpecimen documents specimen disposal and participant deletion after withdrawal with an indicative US$75,000 Starter price and US$35,000-plus annual support, while REDCap software is available at no cost to consortium partners with configurable records and audit trails.
- The incumbent service still operates: the successor reported more than eleven million consented research participants in October 2026 and listed Premium Ancestry + Health at a US$89 promotion against US$199 plus US$99 annually, while AncestryDNA showed a US$34 promotion, so a new kit entrant faces labs, validation and price competition.
- Privacy and security terms are now explicit deal terms: more than thirty states initially objected to the asset sale before court approval, California announced a US$6 million settlement with Chrome and reiterated deletion, sample-destruction and research-withdrawal choices, and ICO infringements were only ended by improvements through end of 2024.